Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e344-

  Nikan, Mehran ^a   Osborn, Maire F ^a   Coles, Andrew H ^a   Godinho, Bruno MDC ^a   Hall, Lauren M ^a   Haraszti, Reka A ^a   Hassler, Matthew R ^a   Echeverria, Dimas ^a   Aronin, Neil ^a   Khvorova, Anastasia ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

drug delivery; neurodegenerative disease; siRNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLOPHILIN B; DOCOSAHEXAENOIC ACID; DOCOSAHEXAENOIC ACID HYDROPHOBICALLY MODIFIED SMALL INTERFERING RNA; HUNTINGTIN; MESSENGER RNA; PHOSPHOPROTEIN DARPP 32; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CELL; CELL VIABILITY; CONJUGATION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG STRUCTURE; DRUG UPTAKE; EMBRYO; FATTY ACID METABOLISM; FEMALE; GENE SILENCING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; INTERNALIZATION; INTRASTRIATAL DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA STRUCTURE; SOLID PHASE SYNTHESIS; BRAIN CORTEX; DRUG CONJUGATION; DRUG SOLUBILITY; DRUG SYNTHESIS; EXTRACELLULAR MATRIX; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; INTERSTITIAL FLUID; MYELIN SHEATH; NUCLEOTIDE SEQUENCE; REVERSED PHASE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; UPREGULATION; WILD TYPE;

EID: 85015168960     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.50     Document Type: Article

References (50)

1. 1 Mathupala, SP, Delivery of small-interfering RNA (siRNA) to the brain. Expert Opin Ther Pat 19 (2009), 137–140.
2. 2 Zukiel, R, Nowak, S, Wyszko, E, Rolle, K, Gawronska, I, Barciszewska, MZ, et al. Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol Ther 5 (2006), 1002–1007.
3. 3 Zhang, Y, Zhang, YF, Bryant, J, Charles, A, Boado, RJ, Pardridge, WM, Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 10 (2004), 3667–3677.
4. 4 Grondin, R, Ge, P, Chen, Q, Sutherland, JE, Zhang, Z, Gash, DM, et al. Onset time and durability of huntingtin suppression in Rhesus putamen after direct infusion of antihuntingtin siRNA. Mol Ther Nucleic Acids, 4, 2015, e245.
5. 5 Shepherd, GM, Corticostriatal connectivity and its role in disease. Nat Rev Neurosci 14 (2013), 278–291.
6. 6 Wang, H, Ghosh, A, Baigude, H, Yang, CS, Qiu, L, Xia, X, et al. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem 283 (2008), 15845–15852.
7. 7 DiFiglia, M, Sena-Esteves, M, Chase, K, Sapp, E, Pfister, E, Sass, M, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 104 (2007), 17204–17209.
8. 8 Grimm, D, The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence, 2, 2011, 8.
9. 9 Krichevsky, AM, Kosik, KS, RNAi functions in cultured mammalian neurons. Proc Natl Acad Sci USA 99 (2002), 11926–11929.
10. 10 Godinho, BM, McCarthy, DJ, Torres-Fuentes, C, Beltrán, CJ, McCarthy, J, Quinlan, A, et al. Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system. Biomaterials 35 (2014), 489–499.
11. 11 Alterman, JF, Hall, LM, Coles, AH, Hassler, MR, Didiot, MC, Chase, K, et al. Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain. Mol Ther Nucleic Acids, 4, 2015, e266.
12. 12 Dyall, SC, Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci, 7, 2015, 52.
13. 13 Glomset, JA, Role of docosahexaenoic acid in neuronal plasma membranes. Sci STKE, 2006, 2006, pe6.
14. 14 Salem, N Jr, Litman, B, Kim, HY, Gawrisch, K, Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36 (2001), 945–959.
15. 15 Bazinet, RP, Layé, S, Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 15 (2014), 771–785.
16. 16 Serhan, CN, Chiang, N, Van Dyke, TE, Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8 (2008), 349–361.
17. 17 Kohli, P, Levy, BD, Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol 158 (2009), 960–971.
18. 18 Calder, PC, Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?. Br J Clin Pharmacol 75 (2013), 645–662.
19. 19 Whitehead, KA, Dahlman, JE, Langer, RS, Anderson, DG, Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng 2 (2011), 77–96.
20. 20 Merendino, N, Costantini, L, Manzi, L, Molinari, R, D'Eliseo, D, Velotti, F, Dietary ω-3 polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer. Biomed Res Int, 2013, 2013, 310186.
21. 21 Siddiqui, RA, Harvey, KA, Xu, Z, Natarajan, SK, Davisson, VJ, Characterization of lovastatin-docosahexaenoate anticancer properties against breast cancer cells. Bioorg Med Chem 22 (2014), 1899–1908.
22. 22 Willibald, J, Harder, J, Sparrer, K, Conzelmann, KK, Carell, T, Click-modified anandamide siRNA enables delivery and gene silencing in neuronal and immune cells. J Am Chem Soc 134 (2012), 12330–12333.
23. 23 Felber, AE, Bayó-Puxan, N, Deleavey, GF, Castagner, B, Damha, MJ, Leroux, JC, The interactions of amphiphilic antisense oligonucleotides with serum proteins and their effects on in vitro silencing activity. Biomaterials 33 (2012), 5955–5965.
24. 24 Byrne, M, Tzekov, R, Wang, Y, Rodgers, A, Cardia, J, Ford, G, et al. Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J Ocul Pharmacol Ther 29 (2013), 855–864.
25. 25 Allerson, CR, Sioufi, N, Jarres, R, Prakash, TP, Naik, N, Berdeja, A, et al. Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 48 (2005), 901–904.
26. 26 Geary, RS, Norris, D, Yu, R, Bennett, CF, Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87 (2015), 46–51.
27. 27 Nelson, PS, Kent, M, Muthini, S, Oligonucleotide labeling methods. 3. Direct labeling of oligonucleotides employing a novel, non-nucleosidic, 2-aminobutyl-1,3-propanediol backbone. Nucleic Acids Res 20 (1992), 6253–6259.
28. 28 Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004), 173–178.
29. 29 Jeong, JH, Mok, H, Oh, YK, Park, TG, siRNA conjugate delivery systems. Bioconjug Chem 20 (2009), 5–14.
30. 30 Harborth, J, Elbashir, SM, Vandenburgh, K, Manninga, H, Scaringe, SA, Weber, K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 13 (2003), 83–105.
31. 31 Yamagami, C, Kawase, K, Iwaki, K, Hydrophobicity parameters determined by reversed-phase liquid chromatography. XV: optimal conditions for prediction of log P(oct) by using RP-HPLC procedures. Chem Pharm Bull (Tokyo) 50 (2002), 1578–1583.
32. 32 Valkó, K, Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J Chromatogr A 1037 (2004), 299–310.
33. 33 Chiu, YL, Ali, A, Chu, CY, Cao, H, Rana, TM, Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 11 (2004), 1165–1175.
34. 34 Berezhna, SY, Supekova, L, Supek, F, Schultz, PG, Deniz, AA, siRNA in human cells selectively localizes to target RNA sites. Proc Natl Acad Sci USA 103 (2006), 7682–7687.
35. 35 Coles, AH, Osborn, MF, Alterman, JF, Turanov, AA, Godinho, BM, Kennington, L, et al. A high-throughput method for direct detection of therapeutic oligonucleotide-induced gene silencing in vivo. Nucleic Acid Ther 26 (2016), 86–92.
36. 36 Roehl, I, Schuster, M, Seiffert, S. Oligonucleotide Detection Method. US 20110201006 A1. Application. 2011.
37. 37 Garden, GA, Möller, T, Microglia biology in health and disease. J Neuroimmune Pharmacol 1 (2006), 127–137.
38. 38 Shitaka, Y, Tran, HT, Bennett, RE, Sanchez, L, Levy, MA, Dikranian, K, et al. Repetitive closed-skull traumatic brain injury in mice causes persistent multifocal axonal injury and microglial reactivity. J Neuropathol Exp Neurol 70 (2011), 551–567.
39. 39 Brown, GC, Neher, JJ, Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 41 (2010), 242–247.
40. 40 Hemmings, HC Jr, Nairn, AC, Aswad, DW, Greengard, P, DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus. J Neurosci 4 (1984), 99–110.
41. 41 Kordasiewicz, HB, Stanek, LM, Wancewicz, EV, Mazur, C, McAlonis, MM, Pytel, KA, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74 (2012), 1031–1044.
42. 42 Kitson, AP, Stark, KD, Duncan, RE, Enzymes in brain phospholipid docosahexaenoic acid accretion: a PL-ethora of potential PL-ayers. Prostaglandins Leukot Essent Fatty Acids 87 (2012), 1–10.
43. 43 Rapoport, SI, Translational studies on regulation of brain docosahexaenoic acid (DHA) metabolism in vivo. Prostaglandins Leukot Essent Fatty Acids 88 (2013), 79–85.
44. 44 Picq, M, Chen, P, Perez, M, Michaud, M, Véricel, E, Guichardant, M, et al. DHA metabolism: targeting the brain and lipoxygenation. Mol Neurobiol 42 (2010), 48–51.
45. 45 Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25 (2007), 1149–1157.
46. 46 Akinc, A, Zumbuehl, A, Goldberg, M, Leshchiner, ES, Busini, V, Hossain, N, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26 (2008), 561–569.
47. 47 Raouane, M, Desmaële, D, Urbinati, G, Massaad-Massade, L, Couvreur, P, Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem 23 (2012), 1091–1104.
48. 48 Kubo, T, Yanagihara, K, Takei, Y, Mihara, K, Morita, Y, Seyama, T, Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity. Mol Pharm 8 (2011), 2193–2203.
49. 49 Damha, MJ, Giannaris, PA, Zabarylo, SV, An improved procedure for derivatization of controlled-pore glass beads for solid-phase oligonucleotide synthesis. Nucleic Acids Res 18 (1990), 3813–3821.
50. 50 Maier, MA, Yannopoulos, CG, Mohamed, N, Roland, A, Fritz, H, Mohan, V, et al. Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting. Bioconjug Chem 14 (2003), 18–29.